Inibidor enzimático (Portuguese Wikipedia)

Analysis of information sources in references of the Wikipedia article "Inibidor enzimático" in Portuguese language version.

refsWebsite

Global rank Portuguese rank

15doi.org

2^nd place

4^th place

13nih.gov

4^th place

8^th place

1wiley.com

222^nd place

196^th place

1web.archive.org

1^st place

doi.org

dx.doi.org

Srinivasan B (fevereiro de 2022). «A guide to enzyme kinetics in early drug discovery». The FEBS Journal. PMID 35175693. doi:10.1111/febs.16404
Copeland RA (março de 2013). «Why Enzymes as Drug Targets? Enzyme are Essential for Life». Evaluation of Enzyme Inhibitors in Drug Discovery: A Guide for Medicinal Chemists and Pharmacologists Second ed. [S.l.]: John Wiley & Sons, Inc. pp. 1–23. ISBN 978-1-118-48813-3. doi:10.1002/9781118540398.ch1
Srinivasan B (fevereiro de 2022). «A guide to enzyme kinetics in early drug discovery». FEBS J: febs.16404. PMID 35175693. doi:10.1111/febs.16404. Consultado em 5 de agosto de 2022. Cópia arquivada em 9 de agosto de 2022
Sauro HM (fevereiro de 2017). «Control and regulation of pathways via negative feedback». Journal of the Royal Society, Interface. 14 (127): 1–13. PMC 5332569. PMID 28202588. doi:10.1098/rsif.2016.0848
Srinivasan B (março de 2021). «Explicit Treatment of Non-Michaelis-Menten and Atypical Kinetics in Early Drug Discovery*». ChemMedChem. 16 (6): 899–918. PMID 33231926. doi:10.1002/cmdc.202000791
Rufer AC (abril de 2021). «Drug discovery for enzymes». Drug Discovery Today. 26 (4): 875–886. PMID 33454380. doi:10.1016/j.drudis.2021.01.006
Schramm VL (novembro de 2018). «Enzymatic Transition States and Drug Design». Chemical Reviews. 118 (22): 11194–11258. PMC 6615489. PMID 30335982. doi:10.1021/acs.chemrev.8b00369
Scapin G (2006). «Structural biology and drug discovery». Current Pharmaceutical Design. 12 (17): 2087–2097. PMID 16796557. doi:10.2174/138161206777585201
Gohlke H, Klebe G (agosto de 2002). «Approaches to the description and prediction of the binding affinity of small-molecule ligands to macromolecular receptors». Angewandte Chemie. 41 (15): 2644–2676. PMID 12203463. doi:10.1002/1521-3773(20020802)41:15<2644::AID-ANIE2644>3.0.CO;2-O
Koppitz M, Eis K (junho de 2006). «Automated medicinal chemistry». Drug Discovery Today. 11 (11–12): 561–568. PMID 16713909. doi:10.1016/j.drudis.2006.04.005
Ciulli A, Abell C (dezembro de 2007). «Fragment-based approaches to enzyme inhibition». Current Opinion in Biotechnology. 18 (6): 489–96. PMC 4441723. PMID 17959370. doi:10.1016/j.copbio.2007.09.003
Satz AL, Kuai L, Peng X (maio de 2021). «Selections and screenings of DNA-encoded chemical libraries against enzyme and cellular targets». Bioorganic & Medicinal Chemistry Letters. 39. 127851 páginas. PMID 33631371. doi:10.1016/j.bmcl.2021.127851
Scarpino A, Ferenczy GG, Keserű GM (2020). «Covalent Docking in Drug Discovery: Scope and Limitations». Current Pharmaceutical Design. 26 (44): 5684–5699. PMID 33155894. doi:10.2174/1381612824999201105164942
Elsässer B, Goettig P (março de 2021). «Mechanisms of Proteolytic Enzymes and Their Inhibition in QM/MM Studies». International Journal of Molecular Sciences. 22 (6). 3232 páginas. PMC 8004986. PMID 33810118. doi:10.3390/ijms22063232
Copeland RA (março de 2013). «Why Enzymes as Drug Targets? Enzyme are Essential for Life». Evaluation of Enzyme Inhibitors in Drug Discovery: A Guide for Medicinal Chemists and Pharmacologists Second ed. [S.l.]: John Wiley & Sons, Inc. pp. 1–23. ISBN 978-1-118-48813-3. doi:10.1002/9781118540398.ch1

nih.gov

ncbi.nlm.nih.gov

Srinivasan B (fevereiro de 2022). «A guide to enzyme kinetics in early drug discovery». The FEBS Journal. PMID 35175693. doi:10.1111/febs.16404
Srinivasan B (fevereiro de 2022). «A guide to enzyme kinetics in early drug discovery». FEBS J: febs.16404. PMID 35175693. doi:10.1111/febs.16404. Consultado em 5 de agosto de 2022. Cópia arquivada em 9 de agosto de 2022
Sauro HM (fevereiro de 2017). «Control and regulation of pathways via negative feedback». Journal of the Royal Society, Interface. 14 (127): 1–13. PMC 5332569. PMID 28202588. doi:10.1098/rsif.2016.0848
Srinivasan B (março de 2021). «Explicit Treatment of Non-Michaelis-Menten and Atypical Kinetics in Early Drug Discovery*». ChemMedChem. 16 (6): 899–918. PMID 33231926. doi:10.1002/cmdc.202000791
Rufer AC (abril de 2021). «Drug discovery for enzymes». Drug Discovery Today. 26 (4): 875–886. PMID 33454380. doi:10.1016/j.drudis.2021.01.006
Schramm VL (novembro de 2018). «Enzymatic Transition States and Drug Design». Chemical Reviews. 118 (22): 11194–11258. PMC 6615489. PMID 30335982. doi:10.1021/acs.chemrev.8b00369
Scapin G (2006). «Structural biology and drug discovery». Current Pharmaceutical Design. 12 (17): 2087–2097. PMID 16796557. doi:10.2174/138161206777585201
Gohlke H, Klebe G (agosto de 2002). «Approaches to the description and prediction of the binding affinity of small-molecule ligands to macromolecular receptors». Angewandte Chemie. 41 (15): 2644–2676. PMID 12203463. doi:10.1002/1521-3773(20020802)41:15<2644::AID-ANIE2644>3.0.CO;2-O
Koppitz M, Eis K (junho de 2006). «Automated medicinal chemistry». Drug Discovery Today. 11 (11–12): 561–568. PMID 16713909. doi:10.1016/j.drudis.2006.04.005
Ciulli A, Abell C (dezembro de 2007). «Fragment-based approaches to enzyme inhibition». Current Opinion in Biotechnology. 18 (6): 489–96. PMC 4441723. PMID 17959370. doi:10.1016/j.copbio.2007.09.003
Satz AL, Kuai L, Peng X (maio de 2021). «Selections and screenings of DNA-encoded chemical libraries against enzyme and cellular targets». Bioorganic & Medicinal Chemistry Letters. 39. 127851 páginas. PMID 33631371. doi:10.1016/j.bmcl.2021.127851
Scarpino A, Ferenczy GG, Keserű GM (2020). «Covalent Docking in Drug Discovery: Scope and Limitations». Current Pharmaceutical Design. 26 (44): 5684–5699. PMID 33155894. doi:10.2174/1381612824999201105164942
Elsässer B, Goettig P (março de 2021). «Mechanisms of Proteolytic Enzymes and Their Inhibition in QM/MM Studies». International Journal of Molecular Sciences. 22 (6). 3232 páginas. PMC 8004986. PMID 33810118. doi:10.3390/ijms22063232

web.archive.org

Srinivasan B (fevereiro de 2022). «A guide to enzyme kinetics in early drug discovery». FEBS J: febs.16404. PMID 35175693. doi:10.1111/febs.16404. Consultado em 5 de agosto de 2022. Cópia arquivada em 9 de agosto de 2022

wiley.com

febs.onlinelibrary.wiley.com

Srinivasan B (fevereiro de 2022). «A guide to enzyme kinetics in early drug discovery». FEBS J: febs.16404. PMID 35175693. doi:10.1111/febs.16404. Consultado em 5 de agosto de 2022. Cópia arquivada em 9 de agosto de 2022